Enhance your treatment decisions with intrinsic subtypes
Put your patients’ prognostic information into action
- Prosigna was developed based on the PAM50 gene signature, which measures the expression of 50 genes to classify tumors into 1 of 4 intrinsic subtypes1
- Intrinsic subtypes provide valuable prognostic information to guide clinical decisions1,2
- According to the St. Gallen guidelines, systemic therapy recommendations should follow intrinsic subtype classification2
Intrinsic subtypes: the underlying biology of breast cancer
PAM50 is the accepted standard for subtyping breast cancer3
The Cancer Genome Atlas (TCGA) research network analyzed the gene expression signatures of 525 breast cancer tumors and clustered them into 4 intrinsic subtypes using 3 methods:
- PAM50 gene signature
- Unsupervised hierarchical clustering
- Semi-supervised hierarchical clustering
PAM50 showed high concordance with both the unsupervised (P<0.001) and the semi-supervised (P<0.001) cluster analyses, supporting PAM50's role as a powerful tool for categorizing breast cancer by intrinsic subtype.
The research concluded that diverse genetic and epigenetic alterations converge phenotypically into the following 4 main breast cancer intrinsic subtypes defined by PAM50: luminal A, luminal B, HER2-enriched, and basal-like.